Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
18 pending office actions • 13 clients • 17 examiners • 9 art units • 0 of 18 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
THE FIRM OF HUESCHEN AND SAGE focuses on Biotechnology & Pharmaceuticals. The firm has 1285 career applications. Its resolved allowance rate is 78.17 percent. This percentage indicates the frequency of patent grants among resolved cases. For a practitioner, this rate describes the firm's historical success in its specified technology fields.
The firm currently manages 14 pending office actions. On average, the firm receives 3.13 office actions per allowance. This 3.13 office actions per allowance figure reflects the typical volume of correspondence required for a grant. The 1285 career applications and 14 pending office actions characterize the firm's total and active prosecution activity. These metrics provide a detailed view of the firm's prosecution history.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (6%) |
| §103 only | 4 (22%) |
| §112 only | 3 (17%) |
| Double-patenting only | 2 (11%) |
| Double-patenting + other | 5 (28%) |
| Multi-statute (no §101) | 3 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 2 | 43.8% | +38.9% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| HAWKINS, AMANDA SALATA | 1 | 12.0% | +45.2% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.6% | +53.8% |
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
| CHENG, KAREN | 1 | 76.3% | +26.7% |
| BREDEFELD, RACHAEL EVA | 1 | 27.4% | +35.0% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | SALVOZA, M FRANCO G | 155d overdue |
| 18937105 | CARBAMOYL PHENYLALANINOL COMPOUNDS AND USES THEREOF | JACKSON, SHAWQUIA | — |
| 18842454 | ENCAPSULATION OF HOP COMPOSITIONS | HAWKINS, AMANDA SALATA | — |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18918219 | IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS | BORI, IBRAHIM D | — |
| 18894074 | CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PECKHAM, RICHARD GRANT | — |
| 18842454 | ENCAPSULATION OF HOP COMPOSITIONS | HAWKINS, AMANDA SALATA | — |
| 18816347 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | WHITE, DAWANNA SHAR-DAY | — |
| 18780629 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | RAMACHANDRAN, UMAMAHESWARI | — |
| 18721923 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | BOWLES, DAVID PAUL | — |
| 18702363 | TRIMETAZIDINE SALTS | CHENG, KAREN | — |
| 18692906 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | BORI, IBRAHIM D | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Servier | 3 |
| Vernalis (R&D) Ltd. | 2 |
| ESTEVE PHARMACEUTICALS, S.A. | 2 |
| Genetic S.p.A. | 2 |
| Axsome Malta Ltd. | 1 |
| Dompé | 1 |
| Kalamazoo Holdings, Inc. | 1 |
| SK Group | 1 |
| Italfarmaco | 1 |
| Axsome Therapeutics | 1 |
| TUFTS MEDICAL CENTER, INC. | 1 |
| SEMENTIS LIMITED | 1 |
| NATIONAL UNIVERSITY OF IRELAND, GALWAY | 1 |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 1693 | 2 |
| 1629 | 1 |
| 3786 | 1 |
| 1628 | 1 |
| 1627 | 1 |
| 1658 | 1 |
| 1672 | 1 |
| 3774 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18937105 | CARBAMOYL PHENYLALANINOL COMPOUNDS AND USES THEREOF | Axsome Malta Ltd. | JACKSON, SHAWQUIA | §101Other | Non-Final OA | — | Pending | Nov 05, 2024 | |
| 18918219 | IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS | Dompé Farmaceutici S.p.A. | BORI, IBRAHIM D | §102§103§112DP | Non-Final OA | — | Pending | Oct 17, 2024 | |
| 18894074 | CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Vernalis (R&D) Ltd. | PECKHAM, RICHARD GRANT | §112 | Non-Final OA | — | Pending | Sep 24, 2024 | |
| 18842454 | ENCAPSULATION OF HOP COMPOSITIONS | Kalamazoo Holdings, Inc. | HAWKINS, AMANDA SALATA | §103§112 | Non-Final OA | — | Pending | Aug 29, 2024 | |
| 18816347 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Vernalis (R&D) Ltd. | WHITE, DAWANNA SHAR-DAY | §103§112DP | Non-Final OA | — | Pending | Aug 27, 2024 | |
| 18780629 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SK Biopharmaceuticals Co., Ltd. | RAMACHANDRAN, UMAMAHESWARI | DP | Non-Final OA | — | Pending | Jul 23, 2024 | |
| 18721923 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | Italfarmaco Spa | BOWLES, DAVID PAUL | §102§103§112DP | Non-Final OA | — | Pending | Jun 20, 2024 | |
| 18702363 | TRIMETAZIDINE SALTS | Les Laboratoires Servier | CHENG, KAREN | 1623 | §103 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18692906 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | Esteve Pharmaceuticals, S.A. | BORI, IBRAHIM D | 1629 | §103DP | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | Axsome Therapeutics, Inc. | BREDEFELD, RACHAEL EVA | 3786 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | Genetic S.p.A. | SZNAIDMAN, MARCOS L | 1628 | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18579645 | PROCESS FOR THE PREPARATION OF BUDESONIDE 21-PHOSPHATE | Genetic S.p.A. | PIHONAK, SARAH | 1627 | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18574801 | PROCESS FOR PREPARING DIOSMIN AND FLAVONOID FRACTION | Les Laboratoires Servier | BERRY, LAYLA D | 1693 | §112 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18554511 | TREATMENT OF NEUROPATHIC CORNEAL PAIN WITH NGF | Tufts Medical Center, Inc. | FISCHER, JOSEPH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | Sementis Limited | SALVOZA, M FRANCO G | 1672 | §103§112 | Final Rejection | 155d overdue | Pending | May 15, 2023 |
| 18004468 | DIOSMIN PREPARATION METHOD | Les Laboratoires Servier | LEE, HOI YAN NMN | 1693 | §103 | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17968253 | CO-CRYSTALS OF TRAMADOL AND COXIBS | Esteve Pharmaceuticals, S.A. | LEE, WILLIAM Y | 1623 | DP | Final Rejection | — | Pending | Oct 18, 2022 |
| 16632453 | STENTED VALVE | National University Of Ireland, Galway | WOZNICKI, JACQUELINE | 3774 | §112 | Non-Final OA | 85d | Pending | Jan 20, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial